Abstract: Provided are compositions and methods for preparing and identifying antibodies having CDR3s that vary in sequence and in length from very short to very long which in certain embodiments may bind to a carbohydrate moiety or the active site of an enzyme. Libraries coding for antibodies with the CDR3s are also provided. The libraries can be provided by modifying a pre-existing nucleic acid library.
Abstract: The invention provides assay methods of detecting plasma protease CI inhibitor (Cl-INH) that binds plasma kallikrein, Factor XII, or both, and uses thereof for identifying subjects at risk for or suffering from a pKal-mediated or bradykinin-mediated disorder. Provided methods permit analysis of patients with plasma kallikrein-mediated angioedema (KMA), or other diseases mediated by pKal useful in the evaluation and treatment.
Abstract: Provided are compositions and methods for preparing and identifying antibodies having CDR3s that vary in sequence and in length from very short to very long which in certain embodiments may bind to a carbohydrate moiety or the active site of an enzyme. Libraries coding for antibodies with the CDR3s are also provided. The libraries can be provided by modifying a pre-existing nucleic acid library.
Abstract: Methods, kits and compositions for diagnosing and treating autoimmue diseases such as rheumatiodi arthritis, Crohn's disease, and ulcerative colitis.
Type:
Grant
Filed:
September 14, 2018
Date of Patent:
May 12, 2020
Assignee:
Dyax Corp.
Inventors:
Daniel J. Sexton, Burt Adelman, Andrew Nixon
Abstract: Disclosed herein are compositions comprising one or more antibodies that specifically bind active plasma kallikrein (e.g., human plasma kallikrein) and methods of using such compositions for the treatment of retinal diseases, such as diabetic macular edema.
Type:
Application
Filed:
August 15, 2019
Publication date:
April 16, 2020
Applicant:
Dyax Corp.
Inventors:
Gregory P. Conley, Andrew Nixon, Daniel J. Sexton
Abstract: Provided herein are methods of treating and preventing hereditary angioedema attack in certain human patient subpopulations using antibodies binding to active plasma kallikrein with specific treatment regimens, for example, at about 300 mg every two weeks. Exemplary human patient subpopulations include female patients, patients less than 18 years old, between 40 and less than 65 years old, adolescent patients, patients who have had one or more prior laryngeal attacks, patients who have had between 1 and 2, 2 and 3, or more than 3 HAE attacks in the four weeks prior to the first dose of the first treatment period; and/or has received treatment with a C1-inhibitor prior to the first treatment period.
Abstract: Focused libraries of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of antibody peptides, polypeptides or proteins and collectively display, display and express, or comprise at least a portion of the focused diversity of the family. The libraries have length and sequence diversities that mimic that found in native human antibodies.
Abstract: Disclosed are methods for identifying desired members from a display libraries, including bacteriophage display libraries. Display library members can be amplified in the presence of a target compound so that cycles of selection can be rapidly completed.
Type:
Grant
Filed:
May 26, 2017
Date of Patent:
March 3, 2020
Assignee:
Dyax Corp.
Inventors:
Robert Charles Ladner, Shannon Hogan, Kristin L. Rookey
Abstract: A eukaryotic expression vector capable of displaying a multi-chain polypeptide on the surface of a host cell is provided, such that the biological activity of the multi-chain polypeptide is exhibited at the surface of the host cell. Such a vector allows for the display of complex biologically active polypeptides, e.g., biologically active multi-chain polypeptides such as immunoglobulin Fab fragments. The present invention describes and enables the successful display of a multi-chain polypeptide on the surface of a eukaryotic host cell. Preferred vectors are described for expressing the chains of a multi-chain polypeptide in a host cell separately and independently (e.g., under separate vector control elements, and/or on separate expression vectors, thus forming a matched vector set).
Type:
Grant
Filed:
July 23, 2018
Date of Patent:
March 3, 2020
Assignee:
Dyax Corp.
Inventors:
Simon E. Hufton, Hendricus Renerus Jacobus Mattheus Hoogenboom
Abstract: Provided herein are methods and kits for analyzing a biological sample obtained from a subject having, suspected of having, or being at risk for a disease associated with the contact activation system.
Type:
Application
Filed:
September 15, 2017
Publication date:
November 28, 2019
Applicant:
Dyax Corp.
Inventors:
Daniel J. Sexton, Malini Viswanathan, Ryan Faucette, Tripti Gaur
Abstract: Disclosed herein are compositions comprising one or more antibodies that specifically bind active plasma kallikrein (e.g., human plasma kallikrein) and methods of using such compositions for the treatment of retinal diseases, such as diabetic macular edema.
Type:
Grant
Filed:
March 26, 2015
Date of Patent:
October 1, 2019
Assignee:
Dyax Corp.
Inventors:
Gregory P. Conley, Andrew Nixon, Daniel J. Sexton
Abstract: Methods are described for preventing or reducing ischemia and/or systemic inflammatory response in a patient such as perioperative blood loss and/or systemic inflammatory response in a patient subjected to cardiothoracic surgery, e.g. coronary artery bypass grafting and other surgical procedures, especially when such procedures involve extra-corporeal circulation, such as cardiopulmonary bypass.
Type:
Application
Filed:
February 21, 2019
Publication date:
August 15, 2019
Applicant:
Dyax Corp.
Inventors:
Robert Charles Ladner, Arthur Charles Ley, Shirish Hirani, Anthony Williams
Abstract: Provided herein are methods and kits for analyzing a biological sample obtained from a subject having, suspected of having, or being at risk for a disease associated with the contact activation system.
Type:
Application
Filed:
September 15, 2017
Publication date:
August 8, 2019
Applicant:
Dyax Corp.
Inventors:
Daniel J. Sexton, Malini Viswanathan, Ryan Faucette, Tripti Gaur
Abstract: A eukaryotic expression vector capable of displaying a multi-chain polypeptide on the surface of a host cell is provided, such that the biological activity of the multi-chain polypeptide is exhibited at the surface of the host cell. Such a vector allows for the display of complex biologically active polypeptides, e.g., biologically active multi-chain polypeptides such as immunoglobulin Fab fragments. The present invention describes and enables the successful display of a multi-chain polypeptide on the surface of a eukaryotic host cell. Preferred vectors are described for expressing the chains of a multi-chain polypeptide in a host cell separately and independently (e.g., under separate vector control elements, and/or on separate expression vectors, thus forming a matched vector set).
Type:
Application
Filed:
July 23, 2018
Publication date:
July 11, 2019
Applicant:
Dyax Corp.
Inventors:
Simon E. Hufton, Hendricus Renerus Jacobus Mattheus Hoogenboom